[{"id":"80c27074-d3d8-4725-96f3-fbf2b5630d87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05584670","created_at":"2022-10-18T14:57:14.377Z","updated_at":"2024-07-02T16:34:59.740Z","phase":"Phase 1/2","brief_title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05584670","lead_sponsor":"Sanofi","biomarkers":" MSI","pipe":" | ","alterations":" HER-2 negative","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • SAR445877"],"overall_status":"Recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 11/29/2022","start_date":" 11/29/2022","primary_txt":" Primary completion: 01/19/2027","primary_completion_date":" 01/19/2027","study_txt":" Completion: 09/27/2028","study_completion_date":" 09/27/2028","last_update_posted":"2024-05-31"},{"id":"2fbb65a4-a780-422e-b302-4dd9315ffcc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05145569","created_at":"2024-06-01T04:17:55.472Z","updated_at":"2024-07-02T16:35:00.527Z","phase":"Phase 2","brief_title":"Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer","source_id_and_acronym":"NCT05145569","lead_sponsor":"Haider Mahdi","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • HCW9218"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-05-29"},{"id":"fbc9f7d7-d0d2-47e2-adf9-dee22a15f587","acronym":"","url":"https://clinicaltrials.gov/study/NCT03721068","created_at":"2021-01-18T18:14:20.673Z","updated_at":"2024-07-02T16:35:08.050Z","phase":"Phase 1","brief_title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","source_id_and_acronym":"NCT03721068","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" IL15","pipe":"","alterations":" ","tags":["IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 06/19/2024","primary_completion_date":" 06/19/2024","study_txt":" Completion: 06/19/2039","study_completion_date":" 06/19/2039","last_update_posted":"2024-04-23"},{"id":"e9a2422f-d4f9-4a61-a157-fe8158579752","acronym":"","url":"https://clinicaltrials.gov/study/NCT05223816","created_at":"2022-02-05T18:29:35.392Z","updated_at":"2024-07-02T16:35:15.881Z","phase":"Phase 2","brief_title":"An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05223816","lead_sponsor":"Virogin Biotech Canada Ltd","biomarkers":" MSI • IDH1","pipe":" | ","alterations":" MSI-H/dMMR • IDH1 mutation","tags":["MSI • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-07"},{"id":"67a15808-0681-4add-b990-145069d8cdb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714372","created_at":"2021-01-19T20:53:07.373Z","updated_at":"2024-07-02T16:35:23.907Z","phase":"Phase 1","brief_title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","source_id_and_acronym":"NCT04714372","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • IDH1 • IDH2 • CD38","pipe":" | ","alterations":" CD38 expression","tags":["FLT3 • IDH1 • IDH2 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-10"},{"id":"5f5b7d90-82b7-4d29-a76d-1af846240ca3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008925","created_at":"2023-08-24T16:11:24.123Z","updated_at":"2024-07-02T16:35:39.126Z","phase":"Phase 1/2","brief_title":"Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer","source_id_and_acronym":"NCT06008925","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • CD8 • IL6 • NCAM1","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • IL6 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-08-24"},{"id":"ee94b79f-8da0-407f-bc94-ca8110bf7bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103631","created_at":"2021-11-02T17:57:08.812Z","updated_at":"2024-07-02T16:35:39.256Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors","source_id_and_acronym":"NCT05103631","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/17/2021","start_date":" 06/17/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2039","study_completion_date":" 12/01/2039","last_update_posted":"2023-08-23"},{"id":"f621ba59-cb59-4206-a05e-20a12949ff48","acronym":"","url":"https://clinicaltrials.gov/study/NCT04377932","created_at":"2021-01-19T19:44:24.215Z","updated_at":"2024-07-02T16:35:43.615Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04377932","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2023-07-07"},{"id":"aa7593a1-12bf-4251-800d-895293ccfc91","acronym":"","url":"https://clinicaltrials.gov/study/NCT04555811","created_at":"2021-01-18T21:46:42.102Z","updated_at":"2024-07-02T16:35:54.835Z","phase":"Phase 1","brief_title":"FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL","source_id_and_acronym":"NCT04555811","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYC • BCL2 • BCL6","pipe":"","alterations":" ","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • FT596"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 02/08/2023","primary_completion_date":" 02/08/2023","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2023-02-23"},{"id":"d2fb6681-a16d-488c-b535-67b0e2be61b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05162118","created_at":"2021-12-17T17:31:15.748Z","updated_at":"2024-07-02T16:36:15.755Z","phase":"Phase 1/2","brief_title":"Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05162118","lead_sponsor":"Zhejiang University","biomarkers":" CD8 • PD-1 • IFNG • IL6 • TNFA • CD4 • NCAM1 • CA 19-9","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • TNFA • CD4 • NCAM1 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/08/2022","start_date":" 03/08/2022","primary_txt":" Primary completion: 03/22/2025","primary_completion_date":" 03/22/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2022-03-09"},{"id":"ae8410e8-deea-4756-9774-18fb45fe7247","acronym":"","url":"https://clinicaltrials.gov/study/NCT04758897","created_at":"2021-02-17T14:01:03.261Z","updated_at":"2024-07-02T16:36:31.185Z","phase":"Phase 1","brief_title":"Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04758897","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • IL15 • NECTIN2","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • CD4 • IL15 • NECTIN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 03/14/2022","primary_completion_date":" 03/14/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-04-27"},{"id":"63367a2e-68e2-4d92-bf7f-8520dd8d4a6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04806464","created_at":"2021-03-19T15:59:01.717Z","updated_at":"2024-07-02T16:36:31.305Z","phase":"Phase 1","brief_title":"Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer","source_id_and_acronym":"NCT04806464","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • PD-1 • CD4 • IL15","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CD4 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/16/2021","start_date":" 03/16/2021","primary_txt":" Primary completion: 03/21/2022","primary_completion_date":" 03/21/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-04-23"}]